Home

Keyvisual giving

 

Link to COMPETE Clinical Trial

COMPETE.
Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

ITM Radiotheranostics Satellite Symposium.

Prof M Caplin, Prof P Ruszniewski, Dr G Nicolas and Dr S Glasberg discussed about “Towards Optimizing the Application of Radiotheranostics in the Management of NET Patients” at ENETS 2019

Watch the Video >>

ITM and United Imaging team up in strategic partnership to cover Chinese and global cancer imaging markets

ITM and UIH to collaborate in marketing and sales of ITM and UIH imaging and related products to clinical customers in China and worldwide.

Read more

Press Releases

ITM receives Pharma Trend Award 2018 "Most Innovative Product"

ITM Isotopen Technologien München AG (ITM), a specialized group of radiopharmaceutical companies, announced today that it has received the Pharma…

Read more

Press Releases

ITM and Merck sign Research Evaluation and Option Agreement to develop Folate Receptor Targeted Radionuclide Therapy

The companies to combine their technologies to develop novel theranostic radiopharmaceuticals.

Merck to supply folate derivatives for the preparation…

Read more

Press Releases

View all news »

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>